In this issue of Cell Stem Cell, Jia et al. (2020) identify residual cancer stem cells (CSCs) as a mechanism of immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC). Remarkably, targeting this population of CSCs can be exploited to potentiate immunotherapy and reduce tumor recurrence and metastasis.

中文翻译：

---

通过靶向癌症干细胞释放免疫疗法。

在本期Cell Stem Cell中，Jia 等人。(2020) 将残留的癌症干细胞 (CSC) 鉴定为头颈部鳞状细胞癌 (HNSCC) 中免疫治疗耐药的一种机制。值得注意的是，靶向该 CSC 群体可用于增强免疫治疗并减少肿瘤复发和转移。